Dianthus Therapeutics DNTH Investment Proceeds
Investment Proceeds at other companies
Other financials
Where this comes from
Reported directly by Dianthus Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities.
The official record: Dianthus Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Dianthus Therapeutics's investment proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Dianthus Therapeutics's investment proceeds?
- Dianthus Therapeutics (DNTH) reported investment proceeds of $104.63M in Q1 2026.
- How has Dianthus Therapeutics's investment proceeds changed year-over-year?
- Dianthus Therapeutics's investment proceeds increased by 27.4% year-over-year, from $82.14M to $104.63M.
- What does investment proceeds mean?
- Cash received from sales, maturities, and redemptions of investment securities across all categories.